VANCOUVER, British Columbia, Jan. 7, 2011 /PRNewswire/ — Enox
Biopharma, Inc. CEO, John C. Rewcastle, Ph.D., will present at the
4th Annual OneMedForum Emerging Company Finance Conference on
Wednesday, January 12 at 8:10 AM PST. The conference is being held
at the Sir Francis Drake Hotel in San Francisco.
Dr. Rewcastle will provide an overview of Enox’s technology and
its ability to embed nitric oxide into polymer based medical
devices rendering them antimicrobial. He will also present the
multibillion dollar market potential of this technology.
“I anticipate a very positive response from our presentation at
OneMedForum,” said Rewcastle. “This conference is attended
principally by CEOs and Investors. The Enox story is attractive to
both these audiences from a licensing and investment prospective,
respectively.”About Enox Biopharma, Inc.
Enox Biopharma, Inc. is an emerging biotechnology company with
proprietary technology that embeds nitric oxide (NO) into polymer
or silicone based medical devices. The innate immune system uses NO
to block microbial growth – embedding NO into medical devices makes
them antimicrobial. Enox’s technology is applicable to any
indwelling polymer medical device including, but not limited to
catheters, endotracheal tubes, tympanostomy tubes and cosmetic
implants. With the current CMS non-coverage of nosocomial
infections the financial burden of infections has shifted to
hospitals who are desperately seeking ways to reduce infection
rates. By utilizing NO, part of the human body’s innate immune
system, Enox Biopharma is improving existing medical devices by
making them antimicrobial.
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements are based on management’s good faith
views and expectations when made. Forwar